Connor, Clark & Lunn Investment Management (CC&L)
BIO icon

Connor, Clark & Lunn Investment Management (CC&L)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,709
Closed -$1.13M – 1215
2022
Q3 		$1.13M Buy
2,709
+1,099
+68% +$548K 0.01% 626
2022
Q2 		$797K Buy
+1,610
New +$839K ﹤0.01% 672
2022
Q1 		– Sell
-2,562
Closed -$1.94M – 1038
2021
Q4 		$1.94M Sell
2,562
-1,455
-36% -$1.09M 0.01% 541
2021
Q3 		$3M Buy
+4,017
New +$3.01M 0.02% 444
2021
Q2 		– Sell
-8,637
Closed -$4.93M – 978
2021
Q1 		$4.93M Sell
8,637
-2,734
-24% -$1.62M 0.03% 358
2020
Q4 		$6.63M Sell
11,371
-4,423
-28% -$2.52M 0.04% 281
2020
Q3 		$8.14M Buy
15,794
+3,664
+30% +$1.86M 0.05% 231
2020
Q2 		$5.48M Sell
12,130
-9,620
-44% -$4.25M 0.04% 278
2020
Q1 		$7.63M Sell
21,750
-75
-0.3% -$27.6K 0.07% 197
2019
Q4 		$8.08M Buy
21,825
+11,400
+109% +$4.02M 0.06% 208
2019
Q3 		$3.47M Buy
10,425
+5,475
+111% +$1.79M 0.02% 318
2019
Q2 		$1.55M Buy
+4,950
New +$1.48M 0.01% 497

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BIO Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2022, closing a stake of 2,709 shares — an estimated $1.13M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BIO in Q2 2019 and held it in 12 quarters. The position peaked at $8.14M in Q3 2020. 472 funds tracked by Wall St. Rank hold BIO as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Bio-Rad Laboratories Class A position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 2,709 Bio-Rad Laboratories Class A shares in Q4 2022, an estimated $1.13M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and held it in 12 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Bio-Rad Laboratories Class A position peaked at $8.14M in Q3 2020.
  • 472 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.